FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB AP	PR	O٧	/AI
--------	----	----	-----

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

transaction was made pursuant to a contract, instruction or written plan for the

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

purchase or sale issuer that is inte	of equity securities of the ended to satisfy the se conditions of Rule enstruction 10.				
1. Name and Addre Mehta Kisha	ess of Reporting Perso	on <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol Benitec Biopharma Inc. [ BNTC ]	1 (2) 1 11 11 11 11 11 11 11 11 11 11 11 11	
11101100 1210110				X Director 10% Owner	
(Last) C/O BENITEC 3940 TRUST W	(First) BIOPHARMA IN /AY	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/01/2025	Officer (give title Other (specify below)	
(Street) HAYWARD	CA	94545	4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person	
(City)	(State)	(Zip)			

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	3 and 4)		(Instr. 4)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	(A) or of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Options (right to buy)	\$12.23	12/01/2025		A		35,000 <sup>(1)</sup>		(2)	12/01/2035	Common Stock	35,000	\$0	35,000	D	

#### Explanation of Responses:

1. Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

2. The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

<u>/s/ Kishan Mehta</u> <u>12/03/2025</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.